Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
This time, the FTC focused on charges for high-cost specialty drugs at the pharmacies of the three biggest PBMS — Cigna's Express Scripts unit, the CVS Health Caremark unit and the UnitedHealth ...
Pharmacy advocate groups are teaming up with lawmakers to get new legislation passed to stop monopolistic behaviors from ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback